Trial Profile

A Multicenter, Randomised, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anaemic Subjects With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 23 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darbepoetin alfa (Primary)
Indications Anaemia
Focus Registrational; Therapeutic Use
Acronyms ARCADE
Sponsors Amgen

Most Recent Events

17 Jun 2018 Results (n=146) presented at the 23rd Congress of the European Haematology Association.
12 Dec 2017 Pooled safety results of NCT00095264 and NCT01362140 (n=352) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
18 Nov 2017 Planned number of patients changed from 141 to 180.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com